Petr Smirnov
Petr Smirnov
PhD Candidate, Medical Biophysics, University of Toronto
Verified email at - Homepage
Cited by
Cited by
PharmacoGx: an R package for analysis of large pharmacogenomic datasets
P Smirnov, Z Safikhani, N El-Hachem, D Wang, A She, C Olsen, ...
Bioinformatics 32 (8), 1244-1246, 2016
Machine learning approaches to drug response prediction: challenges and recent progress
G Adam, L Rampášek, Z Safikhani, P Smirnov, B Haibe-Kains, ...
NPJ precision oncology 4 (1), 1-10, 2020
Dr. VAE: improving drug response prediction via modeling of drug perturbation effects
L Rampášek, D Hidru, P Smirnov, B Haibe-Kains, A Goldenberg
Bioinformatics 35 (19), 3743-3751, 2019
PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies
P Smirnov, V Kofia, A Maru, M Freeman, C Ho, N El-Hachem, GA Adam, ...
Nucleic acids research 46 (D1), D994-D1002, 2018
Revisiting inconsistency in large pharmacogenomic studies
Z Safikhani, P Smirnov, M Freeman, N El-Hachem, A She, Q Rene, ...
F1000Research 5, 2016
Gene isoforms as expression-based biomarkers predictive of drug response in vitro
Z Safikhani, P Smirnov, KL Thu, J Silvester, N El-Hachem, R Quevedo, ...
Nature communications 8 (1), 1-11, 2017
Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer
KL Thu, J Silvester, MJ Elliott, W Ba-Alawi, MH Duncan, AC Elia, AS Mer, ...
Proceedings of the National Academy of Sciences 115 (7), E1570-E1577, 2018
Assessment of pharmacogenomic agreement
Z Safikhani, N El-Hachem, R Quevedo, P Smirnov, A Goldenberg, ...
F1000Research 5, 2016
Integrative cancer pharmacogenomics to infer large-scale drug taxonomy
N El-Hachem, DMA Gendoo, LS Ghoraie, Z Safikhani, P Smirnov, ...
Cancer research 77 (11), 3057-3069, 2017
Integrative Pharmacogenomics Analysis of Patient-Derived XenograftsAnalysis of Patient-Derived Xenografts
AS Mer, W Ba-Alawi, P Smirnov, YX Wang, B Brew, J Ortmann, MS Tsao, ...
Cancer Research 79 (17), 4539-4550, 2019
Modeling Cellular Response in Large-Scale Radiogenomic Databases to Advance Precision RadiotherapyA Radiogenomic Resource to Advance Precision Radiotherapy
VSK Manem, M Lambie, I Smith, P Smirnov, V Kofia, M Freeman, ...
Cancer research 79 (24), 6227-6237, 2019
Safikhani et al. reply
Z Safikhani, N El-Hachem, P Smirnov, M Freeman, A Goldenberg, ...
Nature 540 (7631), E2-E4, 2016
Tissue specificity of in vitro drug sensitivity
F Yao, SA Madani Tonekaboni, Z Safikhani, P Smirnov, N El-Hachem, ...
Journal of the American Medical Informatics Association 25 (2), 158-166, 2018
Drug sensitivity prediction from cell line-based pharmacogenomics data: guidelines for developing machine learning models
H Sharifi-Noghabi, S Jahangiri-Tazehkand, P Smirnov, C Hon, ...
Briefings in Bioinformatics 22 (6), bbab294, 2021
The mevalonate pathway is an actionable vulnerability of t (4; 14)-positive multiple myeloma
J Longo, P Smirnov, Z Li, E Branchard, JE van Leeuwen, JD Licht, ...
Leukemia 35 (3), 796-808, 2021
Stochastic combinatorial ensembles for defending against adversarial examples
GA Adam, P Smirnov, D Duvenaud, B Haibe-Kains, A Goldenberg
arXiv preprint arXiv:1808.06645, 2018
Design of a HIFU array for the treatment of deep venous thrombosis: a simulation study
P Smirnov, K Hynynen
Physics in Medicine & Biology 62 (15), 6108, 2017
Assessment of genetic drift in large pharmacogenomic studies
R Quevedo, P Smirnov, D Tkachuk, C Ho, N El-Hachem, Z Safikhani, ...
Cell systems 11 (4), 393-401. e2, 2020
Personalized diagnosis of medulloblastoma subtypes across patients and model systems
DMA Gendoo, P Smirnov, M Lupien, B Haibe-Kains
Genomics 106 (2), 96-106, 2015
Orchestrating and sharing large multimodal data for transparent and reproducible research
A Mammoliti, P Smirnov, M Nakano, Z Safikhani, C Eeles, H Seo, SK Nair, ...
Nature communications 12 (1), 1-10, 2021
The system can't perform the operation now. Try again later.
Articles 1–20